1. Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines
   PEIFEN FU et al, 2014, Oncology Reports CrossRef
2. Tanshinone IIA decreases the migratory ability of AGS cells by decreasing the protein expression of matrix metalloproteinases, nuclear factor κB-p65 and cyclooxygenase-2
   CHIN-CHENG SU, 2016, Molecular Medicine Reports CrossRef
3. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way
   Jun Xie et al, 2016, BMC Cancer CrossRef
4. PEG–poly(amino acid)s-encapsulated tanshinone IIA as potential therapeutics for the treatment of hepatoma
   Yan Wang et al, 2014, J. Mater. Chem. B CrossRef
5. TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy
   Jinming Zhang et al, 2014, International Journal of Pharmaceutics CrossRef
6. Tanshinone IIA inhibits human gastric carcinoma AGS cell growth by decreasing BiP, TCTP, Mcl-1 and Bcl-xL and increasing Bax and CHOP protein expression
   CHIN-CHENG SU, 2014, International Journal of Molecular Medicine CrossRef
7. Discovery of cancer cell proliferation inhibitors from Salviae miltiorrhizae radix et rhizoma by a trace peak enrichment approach
   Xiao‐wei Zhang et al, 2019, Journal of Separation Science CrossRef
8. Tanshinone IIA increases protein expression levels of PERK, ATF6, IRE1α, CHOP, caspase-3 and caspase-12 in pancreatic cancer BxPC-3 cell-derived xenograft tumors
   Tsung-Lang Chiu et al, 2017, Molecular Medicine Reports CrossRef
9. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo
   Chin-Cheng Su et al, 2016, Oncology Reports CrossRef
10. Translationally controlled tumor protein: the mediator promoting cancer invasion and migration and its potential clinical prospects
    Junying Gao et al, 2022, Journal of Zhejiang University-SCIENCE B CrossRef
11. Tanshinone IIA: Pharmacology, Total Synthesis, and Progress in Structure-modifications
    Xing Huang et al, 2022, Current Medicinal Chemistry CrossRef
12. Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway
    Chin-Cheng Su, 2018, International Journal of Molecular Medicine CrossRef
13. The prevention and treatment effects of tanshinone IIA on oestrogen/androgen-induced benign prostatic hyperplasia in rats
    Chao Wang et al, 2015, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
14. Five‐descriptor model to predict the chromatographic sequence of natural compounds
    Shuying Hou et al, 2016, Journal of Separation Science CrossRef
15. Sodium tanshinone IIA sulfonate prolongs the survival of skin allografts by inhibiting inflammatory cell infiltration and T cell proliferation
    Qingxiong Yu et al, 2014, International Immunopharmacology CrossRef
16. RETRACTED: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway
    Xiaozhong Liao et al, 2020, Frontiers in Oncology CrossRef
17. PEI-PEG-Coated Mesoporous Silica Nanoparticles Enhance the Antitumor Activity of Tanshinone IIA and Serve as a Gene Transfer Vector
    Yinxing Zhu et al, 2021, Evidence-Based Complementary and Alternative Medicine CrossRef
18. Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway
    Huayuan Liu et al, 2021, Scientific Reports CrossRef
19. Tanshinone IIA Inhibits Osteosarcoma Growth through a Src Kinase-Dependent Mechanism
    Chao Hu et al, 2021, Evidence-Based Complementary and Alternative Medicine CrossRef
20. The mechanisms of tanshinone in the treatment of tumors
    Pengyu Zhang et al, 2023, Frontiers in Pharmacology CrossRef